The O-GlcNAc, and N-glycosylation, which use UDP-GlcNAc as a substrate, were examined using western blotting, which revealed that the levels were significantly reduced after nutlin-3a treatment in KRAS MT/p53 WT NSCLC cells (Fig. 5C). This evidence concerns the gene TP53 and non-small cell lung carcinoma.